Studies on protective effects of human paraoxonases 1 and 3 on atherosclerosis in apolipoprotein e knockout mice

Gene Therapy

Volumn 17, Issue 5, 2010, Pages 626-633

  Zhang, C ^a   Peng, W ^a   Wang, M ^b   Zhu, J ^a   Zang, Y ^a   Shi, W ^b   Zhang, J ^a   Qin, J ^a  

^a NANJING UNIVERSITY   (China)

^b JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Antioxidation; Atherosclerosis; Cholesterol efflux; Paraoxonase; Synergistic

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; INTERLEUKIN 1BETA; MALONALDEHYDE; PARAOXONASE 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG EFFICACY; ENZYME BLOOD LEVEL; GENE EXPRESSION; GENE LOCATION; GENE THERAPY; LIPID PEROXIDATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIOXIDANTS; APOLIPOPROTEINS E; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; ESTERASES; GENE THERAPY; GENETIC VECTORS; HUMANS; MACROPHAGES; MALE; MALONDIALDEHYDE; MICE; MICE, KNOCKOUT; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; MUS;

EID: 77952426238     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.11     Document Type: Article

References (37)

1. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79: 360-376.
2. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-241.
3. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004; 37: 1304-1316.
4. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 276: 17527-17535.
5. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004; 11: 412-419.
6. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3(PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000; 275: 33435-33442.
7. Mackness B, Durrington PN, McElduff P, Yarnell J, Azam N, Watt M et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107: 2775-2779.
8. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-287.
9. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106: 484-490.
10. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005; 16: 393-399.
11. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxida-tive role for paraoxonase. J Clin Invest 1998; 101: 1581-1590.
12. Rozenberg O, Shih DM, Aviram M. Human serum paraoxonase (PON1) decreases macrophage cholesterol biosynthesis: a possible role for its phospholipase-A2 activity and lysopho-sphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003; 23: 461-467.
13. Ng CJ, Bourquard N, Hama SY, Shih D, Grijalva VR, Navab M et al. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipo-protein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 1368-1374.
14. Shih DM, Xia YR, Wang XP, Wang SS, Bourquard N, Fogelman AM et al. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res 2007; 100: 1200-1207.
15. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005; 38: 153-163.
16. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46: 1239-1247.
17. Gaidukov L, Tawfik DS. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 2005; 44: 11843-11854.
18. Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005; 353: 9-11.
19. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 656-660.
20. Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, Gleaves LA et al. Increased atherogenesis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci USA 1997; 94: 4647-4652.
21. Wang N, Silver DL, Costet P, Tall AR. Specific binding of ApoA1, enhanced cholesterol efflux and altered plasma membrane morphology in cells expressing ABCA1. J Biol Chem 2000; 275: 33053-33058.
22. Kennedy MA, Barrera GC, Nakamura K, Baldán A, Tarr P, Fishbein MC et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005; 1: 121-131.
23. Draganov DI. Human PON3, effects beyond the HDL. Circ Res 2007; 100: 1104-1105.
24. Liu Y, Mackness B, Mackness M. Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress. Free Radic Biol Med 2008; 45: 743-748.
25. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 1545-1550.
26. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005; 44: 6371-6382.
27. Rosenblat M, Oren R, Aviram M. Lysophosphatidylcholine (LPC) attenuates macrophage mediated oxidation of LDL. Biochem Biophys Res Comm 2006; 344: 1271-1277.
28. Canault M, Peiretti F, Mueller C, Kopp F, Morange P, Rihs S et al. Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis 2004; 172: 211-218.
29. Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H et al. Disruption of tumor. necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005; 180: 11-17.
30. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169: 203-214.
31. Devlin CM, Kuriakose G, Hirsch E, Tabas I. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci USA 2002; 99: 6280-6285.
32. Chi H, Messas E, Levine RA, Graves DT, Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipo-protein E heterozygote model: pharmacotherapeutic implications. Circulation 2004; 110: 1678-1685.
33. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006; 116: 90-100.
34. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov 2008; 7: 143-155.
35. Guns PJ, Assche TV, Verreth W, Fransen P, Mackness B, Mackness M et al. Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipo-protein E-deficient mice with pre-existing atherosclerosis. Brit J Pharmacol 2008; 153: 508-516.
36. Lv HQ, Zhu J, Zang YH, Ze YG, Qin JC. Cloning, high level expression of human paraoxonase-3 in Sf9 cells and pharmacological characterization of its product. Biochem Pharmacol 2005; 70: 1019-1025.
37. Van Eck M, Herijgers N, Van Dijk KW, Havekes LM, Hofker MH, Groot P et al. Effect of macrophage-derived mouse ApoE, human ApoE3-Leiden, and human ApoE2 (Arg1583Cys) on cholesterol levels and atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2000; 20: 119-127.